Post
Imifoplatin by Promontory Therapeutics for Ovarian Cancer: Likelihood of Approval
Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase …
Evinacumab by Ultragenyx Pharmaceutical for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval
Evinacumab is under clinical development by Ultragenyx Pharmaceutical and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH). According to …
UV-1 by Ultimovacs for Epithelial Ovarian Cancer: Likelihood of Approval
UV-1 is under clinical development by Ultimovacs and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase …
Ulixertinib by BioMed Valley Discoveries for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase II for Extrahepatic Bile Duct Cancer. According …
Oxymorphone ER by Avecho Biotechnology for Pain: Likelihood of Approval
Oxymorphone ER is under clinical development by Avecho Biotechnology and currently in Phase II for Pain. According to GlobalData, Phase …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Docetaxel by Meridian Laboratories for Hemolysis: Likelihood of Approval
Docetaxel is under clinical development by Meridian Laboratories and currently in Phase I for Hemolysis. According to GlobalData, Phase I …
Upadacitinib ER by AbbVie for Vitiligo: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase II for Vitiligo. According to GlobalData, Phase II …
Streptococcus vaccine by Minervax for Streptococcal Infections: Likelihood of Approval
Streptococcus vaccine is under clinical development by Minervax and currently in Phase I for Streptococcal Infections. According to GlobalData, Phase …
Tazemetostat hydrobromide by Epizyme for Atypical Teratoid Rhabdoid Tumor: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Epizyme and currently in Phase II for Atypical Teratoid Rhabdoid Tumor. According to …
Tazemetostat hydrobromide by Epizyme for Colorectal Cancer: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Epizyme and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase …
RZ-358 by Rezolute for Hyperinsulinemia: Likelihood of Approval
RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs …
Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval
Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic …
PB-357 by Puma Biotechnology for Breast Cancer: Likelihood of Approval
PB-357 is under clinical development by Puma Biotechnology and currently in Phase I for Breast Cancer. According to GlobalData, Phase …
VEDVDox by ImmunityBio for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
VEDVDox is under clinical development by ImmunityBio and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, …
CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval
CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. …